INTRODUCTION
============

The *Acinetobacter* genus is composed of over 40 named species and nine genomic species \[[@B1][@B2]\]. Among these *Acinetobacter* species, *Acinetobacter baumannii* is the most clinically important pathogen because it is involved in nosocomial infections and often exhibits multidrug resistance, particularly to carbapenems \[[@B3][@B4][@B5]\]. Non-*baumannii Acinetobacter* species have been isolated from patients with bacteremia, endocarditis, and meningitis \[[@B6][@B7][@B8]\]. The clinical features and antibiotic susceptibilities of *A. baumannii* are different from those of non-*baumannii Acinetobacter* species. A previous study on the clinical characteristics of *Acinetobacter infections* found that no cases of infection with non-*baumannii Acinetobacter* species aggravated to severe sepsis or septic shock \[[@B9]\]. The overall antimicrobial susceptibilities of non-*baumannii Acinetobacter* species have been much higher than those of *A. baumannii*. The median number of administered antibiotics was also lower in the non-*baumannii* group \[[@B9][@B10][@B11]\]. Therefore, the accurate identification of *Acinetobacter* species is clinically significant.

The currently available phenotypic identification systems cannot precisely distinguish *Acinetobacter* species. Since *Acinetobacter* species are phenotypically very similar, non-*baumannii Acinetobacter* species are often erroneously identified as *A. baumannii*, resulting in overestimation of the prevalence of *A. baumannii* \[[@B12][@B13]\]. In contrast, several genotypic methods, developed to differentiate *Acinetobacter* species, have been more effective \[[@B14][@B15][@B16]\]. Among these methodologies, the 16S ribosomal RNA (rRNA) and RNA polymerase β-subunit (*rpoB*) gene sequencing approaches have been widely used. The most fairly accurate method for the identification of *Acinetobacter* species was suggested to be *rpoB* gene sequencing, because of the abundance of *rpoB* polymorphisms in these species \[[@B14][@B16][@B17]\]. However, these molecular techniques are laborious, expensive, and time-consuming, making them unsuitable for routine identification of *Acinetobacter* species in clinical laboratories \[[@B2]\].

Matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) mass spectrometry (MS) has been progressively applied for the identification of diverse microorganisms such as bacteria, yeasts, and even mycobacteria in clinical microbiology laboratories \[[@B18][@B19]\]. MALDI-TOF MS yields unique mass spectral fingerprints of these microorganisms that can be compared with a database of established fingerprints, thus enabling accurate identification \[[@B18]\]. This method is simple, fast, and cost-effective, requiring only small amounts of samples \[[@B20]\]. Although several studies have attempted to adapt MALDI-TOF MS for the identification of *Acinetobacter* species, MALDI-TOF MS was insufficient for species-level identification of *Acinetobacter* because of limited databases \[[@B2][@B20]\].

Therefore, we generated an improved database and evaluated the ability of MALDI-TOF MS in conjunction with our new database to identify a broad range of clinical *Acinetobacter* species, based on the results of *rpoB* sequencing.

METHODS
=======

1. Bacterial isolates
---------------------

A total of 729 *Acinetobacter* clinical isolates collected between January 2012 and May 2015 at 32 university hospitals in Korea were included in this study. The isolates were composed of 447 *A. baumannii*, 146 *A. nosocomialis*, 78 *A. pittii*, 18 *A. ursingii*, 9 *A. bereziniae*, 9 *A. soli*, 4 *A. johnsonii*, 4 *A. radioresistens*, 3 *A. gyllenbergii*, 3 *A. haemolyticus*, 2 *A. lwoffii*, 2 *A. junii*, 2 *A. venetianus*, and 2 *A. genomospecies* 14TU. After 212 strains (28 *A. baumannii*, 110 *A. nosocomialis*, 55 *A. pittii*, 3 *A. ursingii*, 3 *A. bereziniae*, 3 *A. soli*, 2 *A. johnsonii*, 2 *A. radioresistens*, 1 *A. gyllenbergii*, 1 *A. haemolyticus*, 1 *A. lwoffii*, 1 *A. junii*, 1 *A. venetianus*, and 1 *A. genomospecies* 14TU) were tested with the default Bruker database, the profiles of 63 *Acinetobacter* strains (31 *A. nosocomialis*, 11 *A. pittii*, 6 *A. bereziniae*, 6 *A. soli*, 2 *A. ursingii*, 1 *A. gyllenbergii*, 1 *A. haemolyticus*, 2 *A. junii*, 1 *A. venetianus*, and 2 *A. genomospecies* 14TU) were added to the database. The updated 63 *Acinetobacter* strains are presented in [Fig. 1](#F1){ref-type="fig"}. The *rpoB* sequence of each of the updated 63 *Acinetobacter strains* showed more than 99.0% identity with that of the closest species. Additionally, 517 *Acinetobacter* isolates (419 *A. baumannii*, 36 *A. nosocomialis*, 23 *A. pittii*, 15 *A. ursingii*, 6 *A. bereziniae*, 6 *A. soli*, 2 *A. johnsonii*, 2 *A. radioresistens*, 2 *A. gyllenbergii*, 2 *A. haemolyticus*, 1 *A. lwoffii*, 1 *A. junii*, 1 *A. venetianus*, and 1 *A. genomospecies* 14TU) were assayed for validation. These clinical isolates were deposited in the National Culture Collection for Pathogens, supervised by the Korean Centers for Disease Control and Prevention. All strains were stored at -80℃; well-isolated colonies were used for all experiments after growth on MacConkey agar for 12-24 hr at 37℃.

2. Species identification of *Acinetobacter* isolates
-----------------------------------------------------

Species were identified by using the Vitek 2 system (bioMérieux Vitek Inc., Hazelwood, MO, USA) and/or 16S rRNA and *rpoB* sequencing \[[@B14][@B16]\]. These sequences were compared against sequence databases by using a Basic Local Alignment Search Tool (BLAST) (<http://blast.ncbi.nlm.nih.gov/Blast>) \[[@B20]\]. Additional PCR amplification of *bla*~OXA-51~ was conducted to confirm *A. baumannii* \[[@B21]\].

3. MALDI-TOF MS
---------------

### 1) Bacterial extraction

Samples were prepared as previously described \[[@B20]\]. A 1-µL sterile loop was used to transfer each colony into 300 µL of distilled water, after which 900 µL of absolute ethanol was added. The suspension was centrifuged at 12,000*g* for 2 min and the resultant supernatant was discarded. After the pellet was dried at room temperature, 50 µL of 70% formic acid (Sigma-Aldrich, St. Louis, MO, USA) was added. The mixture was vortexed vigorously to yield a homogeneous solution. Finally, 50 µL of acetonitrile (Sigma-Aldrich) was added, and the mixture was centrifuged at 12,000g for 2 min.

### 2) Species identification of bacterial extracts

One microliter of each prepared bacterial extract was spotted onto a stainless steel target plate (Bruker Daltonics GmbH, Leipzig, Germany) and was dried at room temperature for 10 min. Next, 1 µL of matrix solution (consisting of alpha-cyano-4-hydroxycinnamic acid, absolute acetonitrile and trifluoroacetic acid) was placed onto the sample. The solution and sample were allowed to co-crystallize for 10 min at room temperature. The prepared samples were analyzed by using a MicroFlex LT mass spectrometer (Bruker Daltonics), which was operated using Flex control software (version 3.4; Bruker Daltonics). Calibration was conducted by using the Bacterial Test Standard (Bruker Daltonics) as recommended by the manufacturer.

### 3) Data analysis

Each prepared sample was analyzed on a MALDI Biotyper RTC (version 3.1; Bruker Daltonics); mass spectra were evaluated with Flex control software (Bruker Daltonics). Each mass spectrum was searched against the default Bruker database and against the updated database. The log score identification criteria, originating in the alignment of peaks to the best matching reference data, were classified as follows: ≥2.3, highly probable species; between 2.0 and 2.3, secure genus and probable species; between 1.7 and 2.0, probable genus; and \<1.7, non-reliable identification. The dendrogram of the *Acinetobacter* isolates was constructed by using the correlation distance measurements and the average linkage algorithm settings of MALDI Biotyper3 (version 3.1; Bruker Daltonics).

### 4) Library modification

Samples were prepared by using a Standard ethanol/formic acid extraction protocol as described earlier. One microliter of bacterial extract from each of the 63 *Acinetobacter* strains was spotted eight times onto a stainless steel target plate (Bruker Daltonics) and was dried for 10 min at room temperature. One microliter of matrix solution was also spotted onto each prepared sample. After drying at room temperature for 10 min, each spot was measured three times. The obtained 24 spectra were analyzed with Flex analysis software (version 3.4; Bruker Daltonics). Accurately determined mass spectra were uploaded into the MALDI Biotyper3 software (Bruker Daltonics) to create mean spectra (MSP) for *Acinetobacter* species according to the Biotyper MSP creation standard method.

RESULTS
=======

The analyzed results with log score values are presented in [Table 1](#T1){ref-type="table"}. The species identification, which was confirmed by *rpoB* and 16S rRNA sequencing, has shown that MALDI-TOF MS yielded 69.8% (148/212) accuracy of identification at the species level with the default Bruker database and 100.0% (517/517) with the improved database for all of the studied isolates. When a log score of 2.0 was set as the cut-off value for probable species identification, the concordance rate between MALDI-TOF MS and sequencing increased from 72.4% (105/145) with the default Bruker database to 100.0% (514/514) with the improved database. Furthermore, if only the results of log score above 2.3 were included for reliable species identification, the concordance rate between MALDI-TOF MS and sequencing was elevated from 90.2% (55/61) with the default Bruker database to 100.0% (451/451) with the improved database.

Among the 64 discordant results for species identification with the default Bruker database, 49 *A. nosocomialis* and 5 *A. pittii* were erroneously identified as *A. baumannii*. The other 3 *A. bereziniae*, 3 *A. soli*, 1 *A. gyllenbergii*, 1 *A. junii*, 1 *A. venetianus*, and 1 *A. genomospecies* 14TU were misidentified as *A. nosocomialis*, *A. baumannii*, *A. baylyi*, *A. gyllenbergii*, or could not be identified by MALDI-TOF MS. In contrast, none of the 517 *Acinetobacter* strains for validation were misidentified when they were searched against the improved database using MALDI-TOF MS. Furthermore, the proportion of scores above 2.0 among the accurately identified isolates at the species level was 70.9% (105/148) using the default Bruker database, while the proportion was 99.4% when using improved database of MALDI-TOF MS (514/517). In particular, the proportion with log scores above 2.0 among the accurately identified *A. nosocomialis* increased from 50.8% (31/61) to 100.0% (36/36), and that of *A. pittii* increased from 76.0% (38/50) to 100.0% (23/23).

Representative mass spectra of 16 *Acinetobacter* species, generated by the Flex analysis (Bruker Daltonics), are presented in [Fig. 2](#F2){ref-type="fig"}. In addition, a dendrogram was constructed by using 63 updated isolates from the improved database ([Fig. 1](#F1){ref-type="fig"}). *A. bereziniae*, *A. soli*, *A. gyllenbergii*, *A. junii*, *A. venetianus*, and *A. genomospecies* 14TU, which were not included in the default Bruker database, are present in the dendrogram. A dendrogram, consisting of *A. baumannii*, *A. nosocomialis*, and *A. pittii* in the improved database, is shown in [Fig. 3](#F3){ref-type="fig"}. Cluster analysis indicated that the protein signatures from *A. baumannii* species comprised a separate cluster, except those from *A. baumannii* CS 62_1 BRB, and were more closely related to those from *A. nosocomialis* than those from *A. pittii*.

DISCUSSION
==========

MALDI-TOF MS has been effective in identifying a broad spectrum of microorganisms, including bacteria, yeasts, and molds \[[@B18][@B19]\]. However, identification rates for *Acinetobacter* species have been suboptimal; only 72.4% (89/123) of studied *Acinetobacter* isolates were accurately identified \[[@B2]\]. In the present study, 72.4% (105/145) of *Acinetobacter* strains were validly identified at the species level if a log score of 2.0 was set as the cut-off value with the default Bruker database.

Most of the 64 discordant results consisted of 49 *A. nosocomialis* and 5 *A. pittii*, which were misidentified as *A. baumannii* by MALDI-TOF MS. Insufficient *A. nosocomialis* and *A. pittii*-specific protein signatures in the default Bruker database is one potential explanation for these identification failures. Kishii et al. \[[@B2]\] reported that the sensitivity improved from 74.8% to 82.4% after updating the default database with *A. nosocomialis* and *A. pittii* signatures. Additionally, 98.3% (59/60) of *Acinetobacter* isolates were identified at the species level, by using a local database that incorporated the specific signature profiles for *A. nosocomialis* into the default Bruker database, according to the process described by Espinal et al. \[[@B20]\]. In the present study, the overall concordance rate between MALDI-TOF MS and *rpoB* sequencing for the identification of *Acinetobacter* species was substantially increased from 69.8% (148/212) to 100.0% (517/517) after more diverse representative signatures were included within the default database.

Of particular note, all of the *A. nosocomialis* (36/36) and *A. pittii* (19/19) isolates were successfully identified after including a wide range of *A. nosocomialis* and *A. pittii* mass spectra into the default database. Moreover, database modification increased the proportion of scores above 2.0 among the correctly identified isolates from 70.9% (105/148) to 99.4% (514/517), further indicating the reliability of our results.

Three *A. bereziniae*, three *A. soli*, one *A. gyllenbergii*, one *A. junii*, one *A. venetianus*, and one *A. genomospecies* 14TU isolates were identified by MALDI-TOF MS after the incorporation of their protein signatures into the default Bruker database. These species could not previously be properly identified because of their absence in the default library. Kishii et al. \[[@B2]\] also correctly identified *A. bereziniae* and *A. soli* by MALDI-TOF MS, which had been misidentified as *A. guillouiae* and *A. baylyi*, after updating their original library.

Although the dendrogram showed that *A. baumannii* and *A. nosocomialis* were more closely related to each other than to other *Acinetobacter* species, these two species obviously formed separate clusters and MALDI-TOF MS analysis enabled the unambiguous identification of these two strains.

Peak analysis of representative *Acinetobacter* species yielded sufficient differences among their protein signatures for accurate MALDI-TOF MS-based identification. In the present study, the 5,749.1 m/z peak for *A. baumannii*; the 4,070.5 m/z and 8,139.0 m/z peaks for *A. nosocomialis*; and the 2,891.8 m/z, 4,412.6 m/z, and 5,760.0 m/z peaks for *A. pittii* were specific and similar to those reported in previous studies. Hsueh et al. \[[@B22]\] found that the 2,875.03 m/z and 5,749.51 m/z peaks were specific for *A. baumannii*; the 4,070.04 m/z and 8,137.58 m/z peaks were specific for *A. nosocomialis*; and the 2,889.87 m/z, 4,412.56 m/z, and 5,779.52 m/z peaks were specific for *A. pittii*. Šedo et al. \[[@B23]\] also reported that the 5,748 m/z peak was specific for *A. baumannii*.

The clinical relevance of non-*baumannii Acinetobacter* has been shown to differ substantially from that of *A. baumannii* \[[@B1]\]. Non-*baumannii Acinetobacter* species tend to be less prevalent than *A. baumannii*, although the prevalence of each *Acinetobacter* species may differ geographically. The majority of nosocomial *Acinetobacter* species isolated from patients during a 3-yr surveillance program were identified as *A. baumannii* (84.5%), whereas only 5.6% of infections were caused by *A. pittii* \[[@B24]\]. Turton et al. \[[@B12]\] also reported that most isolates were identified as *A. baumannii* (78%) among 690 *Acinetobacter* strains, whereas the incidences of *A. lwoffii*, *A. ursingii*, and *A. pittii* were 8.8%, 4%, and 1.7%, respectively. Our *Acinetobacter* isolates for validation consisted of 81.0% *A. baumannii* (419/517), 7.0% *A. nosocomialis* (36/517), and 4.4% *A. pittii* (23/517) strains, a finding that is consistent with previous results. The first group of 212 *Acinetobacter* species was mainly used for the verification of non-*baumannii Acinetobacter* species, which had been erroneously identified by MALDI-TOF MS. On the other hand, the second group, which consisted of 517 *Acinetobacter* species, was randomly collected specifically for the purpose of validating the improved database, and is therefore, a more descriptive of the prevalence of *Acinetobacter* species. The limitation of the present study was the use of two separate groups with differing strain distributions and numbers in evaluating the default and improved databases. A study analyzing the same groups with both the default and improved databases concurrently would provide a more accurate assessment of *Acinetobacter* prevalence.

With respect to clinical characteristics, *A. baumannii* has predominantly accounted for nosocomial infection outbreaks in intensive care units (ICU), although *A. nosocomialis*, *A. pittii*, and *A. ursingii* have also caused outbreaks \[[@B25][@B26][@B27]\]. The rates of ICU admissions (15.4% vs. 50.0%), hospital-acquired infections (76.9% vs. 97.2%), and mortality (16.7% vs. 58.6%) were significantly greater in the *A. baumannii* group than in the non-*A. baumannii* group \[[@B9][@B11]\]. Moreover, Park et al. \[[@B28]\] found that *A. baumannii* infection was an independent predictor of mortality in patients with *Acinetobacter* bacteremia, a finding that further emphasizes the importance of correct species identification of *Acinetobacter* species.

Further, the antimicrobial susceptibilities of non-*baumannii Acinetobacter* species have been shown to differ greatly from those of *A. baumannii*. The resistance rates of *A. nosocomialis*and *A. pittii* to imipenem have been found to be 31% (4/13) and 6.7% (1/15), respectively, while that of *A. baumannii* was 66% (35/53) \[[@B29]\]. The overall rates of imipenem and/or meropenem resistance of the non-*baumannii Acinetobacter* isolates was 2.6% according to a previous report \[[@B14]\]. These differences likely originate from the different carbapenemases expressed by *A. baumannii* versus non-*A. baumannii* species \[[@B1]\]. Of particular interest, *A. baumannii* intrinsically harbors *bla*~OXA-51~, which can be used to differentiate *A. baumannii* from other *Acinetobacter* species. Additionally, Lee et al. \[[@B30]\] found that non-*baumannii Acinetobacter* isolates were more resistant to colistin than *A. baumannii*. Colistin has been widely used to treat *A. baumannii* infections; however, *A. genomospecies* 14TU is intrinsically resistant to colistin \[[@B31]\].

Taken together, accurate identification of *Acinetobacter* species is essential for appropriate management, which influences clinical outcomes. We demonstrated that refining the default MALDI-TOF MS database enabled the rapid and correct identification of *Acinetobacter* strains at the species level, thereby demonstrating the potential of this approach as an alternative to the use of laborious genotypic tools. In the present study, *A. nosocomialis* and *A. pittii* were the two most prevalent species after *A. baumannii*. These two species could be differentiated by MALDI-TOF MS by incorporating more diverse *A. nosocomialis* and *A. pittii* mass spectra. *A. bereziniae*, *A. soli*, *A. gyllenbergii*, *A. junii*, *A. venetianus*, and *A. genomospecies* 14TU were also identified after the default library was complemented with their missing protein signatures. Furthermore, to the best of our knowledge, this is the first demonstration of the correct identification of *A. gyllenbergii*, *A. venetianus*, and *A. genomospecies* 14TU clinical isolates by MALDI-TOF MS. Although this study could not include all of the *Acinetobacter* species nor a sufficient number of strains of rare *Acinetobacter* species, our data indicate that *Acinetobacter* species isolated in the clinical settings could be correctly identified. Moreover, the present study included a wide range of clinical isolates from various university hospitals, likely reflecting the diversity of species submitted to actual clinical laboratories.

In conclusion, our study showed that MALDI-TOF MS is an efficient technique for the accurate and rapid identification of *Acinetobacter* strains at the species level after library modification. The updated database, achieved by inclusion of more diverse and specific protein signatures for each *Acinetobacter* species into the default Bruker library, is required for correct species identification. The misidentification of clinical *Acinetobacter* isolates could lead to significant outcomes such as aggravation of infection or even death, given that the clinical relevance and antimicrobial susceptibilities of these species differ greatly. Therefore, MALDI-TOF MS has the potential to become an essential technique, by which clinical microbiology laboratories routinely identify *Acinetobacter* species.
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![Dendrogram of the protein signatures of the updated 63 *Acinetobacter* strains, derived from matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS) data. *A. bereziniae*, *A. soli*, *A. gyllenbergii*, *A. junii*, *A. venetianus*, and *A. genomospecies* 14TU that were not in the default Bruker database are presented. All distance values are relative and normalized to a maximal value of 1,000.](alm-36-325-g001){#F1}

![Peak profiles of 15 representative *Acinetobacter* species generated by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). The mass-to-charge (m/z) ratios of the ions are shown on the x-axis, and the absolute intensities of the ions are presented on the y-axis. AU values were given by the software.\
Abbreviation: AU, arbitrary intensity.](alm-36-325-g002){#F2}

![Dendrogram constructed from the specific matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF-MS)-generated mass spectra of *A. baumannii*, *A. nosocomialis*, and *A. pittii* within the improved database (which includes the original Bruker database). The protein profiles from *A. baumannii* isolates formed a separate cluster. The *A. baumannii* protein profiles were more closely associated with those from *A. nosocomialis* than those from *A. pittii*. All relative distance values are normalized to a maximal value of 1,000.](alm-36-325-g003){#F3}

###### Identification of *Acinetobacter* species and the associated log score values, obtained by using MALDI-TOF MS

![](alm-36-325-i001)

  Acinetobacter species     Default bruker database   Improved database^\*^                                                                                                                  
  ------------------------- ------------------------- ----------------------- -------------- -------------- -------------------- ----------------- --------------- ------------- ----------- ---------------------
  *A. baumannii*            100.0 (22/22)^†^          100.0 (5/5)             100.0 (1/1)    0.0 (0/0)      100.0 (28/28)        100.0 (376/376)   100.0 (43/43)   0.0 (0/0)     0.0 (0/0)   100.0 (419/419)
  *A. nosocomialis*         85.7 (12/14)              38.0 (19/50)            70.4 (19/27)   57.9 (11/19)   55.5 (61/110)        100.0 (36/36)     0.0 (0/0)       0.0 (0/0)     0.0 (0/0)   100.0 (36/36)
  *A. pittii*               94.1 (16/17)              100.0 (22/22)           80.0 (8/10)    66.7 (4/6)     90.9 (50/55)         100.0 (19/19)     100.0 (4/4)     0.0 (0/0)     0.0 (0/0)   100.0 (23/23)
  *A. ursingii*             100.0 (3/3)               0.0 (0/0)               0.0 (0/0)      0.0 (0/0)      100.0 (3/3)          100.0 (5/5)       100.0 (8/8)     100.0 (2/2)   0.0 (0/0)   100.0 (15/15)
  *A. bereziniae*           0.0 (0/1)                 0.0 (0/1)               0.0 (0/0)      0.0 (0/1)      0.0 (0/3)            100.0 (6/6)       0.0 (0/0)       0.0 (0/0)     0.0 (0/0)   100.0 (6/6)
  *A. soli*                 0.0 (0/0)                 0.0 (0/0)               0.0 (0/2)      0.0 (0/1)      0.0 (0/3)            100.0 (2/2)       100.0 (3/3)     100.0 (1/1)   0.0 (0/0)   100.0 (6/6)
  *A. johnsonii*            0.0 (0/0)                 100.0 (2/2)             0.0 (0/0)      0.0 (0/0)      100.0 (2/2)          0.0 (0/0)         100.0 (2/2)     0.0 (0/0)     0.0 (0/0)   100.0 (2/2)
  *A. radioresistens*       100.0 (1/1)               100.0 (1/1)             0.0 (0/0)      0.0 (0/0)      100.0 (2/2)          100.0 (1/1)       100.0 (1/1)     0.0 (0/0)     0.0 (0/0)   100.0 (2/2)
  *A. gyllenbergii*         0.0 (0/0)                 0.0 (0/1)               0.0 (0/0)      0.0 (0/0)      0.0 (0/1)            100.0 (1/1)       100.0 (1/1)     0.0 (0/0)     0.0 (0/0)   100.0 (2/2)
  *A. haemolyticus*         0.0 (0/0)                 100.0 (1/1)             0.0 (0/0)      0.0 (0/0)      100.0 (1/1)          100.0 (2/2)       0.0 (0/0)       0.0 (0/0)     0.0 (0/0)   100.0 (2/2)
  *A. lwoffii*              100.0 (1/1)               0.0 (0/0)               0.0 (0/0)      0.0 (0/0)      100.0 (1/1)          100.0 (1/1)       0.0 (0/0)       0.0 (0/0)     0.0 (0/0)   100.0 (1/1)
  *A. junii*                0.0 (0/1)                 0.0 (0/0)               0.0 (0/0)      0.0 (0/0)      0.0 (0/1)            100.0 (1/1)       0.0 (0/0)       0.0 (0/0)     0.0 (0/0)   100.0 (1/1)
  *A. venetianus*           0.0 (0/1)                 0.0 (0/0)               0.0 (0/0)      0.0 (0/0)      0.0 (0/1)            100.0 (1/1)       0.0 (0/0)       0.0 (0/0)     0.0 (0/0)   100.0 (1/1)
  *A. genomospecies* 14TU   0.0 (0/0)                 0.0 (0/1)               0.0 (0/0)      0.0 (0/0)      0.0 (0/1)            0.0 (0/0)         100.0 (1/1)     0.0 (0/0)     0.0 (0/0)   100.0 (1/1)
  Total (%)                 90.2 (55/61)              59.5 (50/84)            70.0 (28/40)   55.6 (15/27)   **69.8 (148/212)**   100.0 (451/451)   100.0 (63/63)   100.0 (3/3)   0.0 (0/0)   **100.0 (517/517)**

^\*^The improved database consisted of the default Bruker database with the addition of representative mass spectra from 63 *Acinetobacter* strains; ^†^(Number of concordant results between MALDI-TOF MS and *rpoB* gene sequencing/Number of all studied isolates confirmed by sequencing).

Abbreviations: MALDI-TOF MS, matrix-assisted laser desorption ionization-time of flight mass spectrometry.
